Paladin's Premium Offer Remains the Best Choice for Afexa Shareholders
- 57% premium to recent share price - Provides fair value, liquidity and certainty
(firmenpresse) - MONTREAL, QUEBEC -- (Marketwire) -- 08/29/11 -- Paladin Labs Inc. ("Paladin" or the "Company") (TSX: PLB), a leading Canadian diversified specialty pharmaceutical company, today reminded shareholders of Afexa Life Sciences Inc. ("Afexa")(TSX: FXA) of the benefits of Paladin's offer to acquire any and all of Afexa's issued and outstanding shares for $0.55 per share (the "Offer").
"Our Offer provides immediate fair value, liquidity and certainty for Afexa shareholders. The Afexa Board's response in its Directors' Circular is largely based on management's expectations and assertions about the future performance of Afexa." said Mark Beaudet, interim President and Chief Executive Officer of Paladin. "When considering the Paladin Offer and the Afexa Board's recommendation, shareholders should examine Afexa's actual track record. Afexa has consistently failed to meet the targets that its management has provided to investors."
"COLD-FX® would be a good addition to Paladin's product portfolio but, as the primary engine of Afexa's revenue, it has stalled," said Mr. Beaudet. "Paladin believes it is offering full value for an established but mature core product and an unproductive pipeline of potential products. Based on Afexa's past performance and failure to deliver on objectives, shareholders should critically examine management's assertions that there will be a significant change in Afexa's fortunes in the future."
Through the Paladin Offer, Afexa shareholders can be opportunistic. The Offer gives Afexa shareholders choices: One is the opportunity to receive cash or shares in a better-performing company at a substantial premium and fair valuation. The other choice is to continue to hold an illiquid investment with declining value.
"A realistic appraisal of Afexa and its prospects reveals the actual value in the company. Our analysis shows that Paladin is offering Afexa shareholders a fair price for that value," Mr. Beaudet said.
About the Offer
The Paladin Offer is open until 8:00 p.m. Toronto time on September 15, 2011 and has minimal and customary conditions. The Offer has no minimum tender condition and is not subject to due diligence or financing conditions.
Full details of the Offer are available in the offer to purchase and take-over bid circular that has been sent to Afexa shareholders and filed on SEDAR. The Offer and related documents are available at and through Paladin's website, or at .
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol PLB. More information is available at .
This press release may contain forward-looking statements and predictions. These forward-looking statements, including any statements as to Afexa's acquisition by Paladin, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company's Annual Information Form for the year ended December 31, 2010. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly fillings, annual report and Annual Information Form and other fillings found on SEDAR at . The information in this announcement concerning Afexa and its assets and projects is based on publicly available information and has not been independently verified by Paladin.
Contacts:
Media
John Lute
Lute & Company
416-929-5883
Afexa Shareholders
Information Agent for Paladin Labs Inc.
Phoenix Advisory Partners
1-800-591-8263 (toll free in North America)
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.08.2011 - 06:30 Uhr
Sprache: Deutsch
News-ID 1034562
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
MONTREAL, QUEBEC
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 121 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Paladin's Premium Offer Remains the Best Choice for Afexa Shareholders
"
steht unter der journalistisch-redaktionellen Verantwortung von
Paladin Labs Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
